MARIA JESUS
PEÑARRUBIA PONCE
PROFESOR ASOCIADO
Hospital Vall d'Hebron
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (9)
2024
-
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 17, pp. 3704-3714
2021
-
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia
Blood, Vol. 137, Núm. 14, pp. 1879-1894
2020
-
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia
European Journal of Haematology, Vol. 104, Núm. 3, pp. 259-270
2017
-
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice
International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516
2016
-
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302
2015
-
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43
-
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
Cancer Medicine, Vol. 4, Núm. 7, pp. 995-1002
2014
-
Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?
American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211
2003
-
A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: No differences in cytogenetic responses
Annals of Hematology, Vol. 82, Núm. 12, pp. 750-758